Literature DB >> 31302785

Health sequelae of human cryptosporidiosis-a 12-month prospective follow-up study.

B L Carter1, R E Stiff2, K Elwin3, H A Hutchings1, B W Mason1,4, A P Davies1,3, R M Chalmers5.   

Abstract

To investigate long-term health sequelae of cryptosporidiosis, with especial reference to post-infectious irritable bowel syndrome (PI-IBS). A prospective cohort study was carried out. All patients with laboratory-confirmed, genotyped cryptosporidiosis in Wales, UK, aged between 6 months and 45 years of age, over a 2-year period were contacted. Five hundred and five patients agreed to participate and were asked to complete questionnaires (paper or online) at baseline, 3 and 12 months after diagnosis. The presence/absence of IBS was established using the Rome III criteria for different age groups. Two hundred and five of 505 cases completed questionnaires (40% response rate). At 12 months, over a third of cases reported persistent abdominal pain and diarrhoea, 28% reported joint pain and 26% reported fatigue. At both 3 and 12 months, the proportion reporting fatigue and abdominal pain after Cryptosporidium hominis infection was statistically significantly greater than after C. parvum. Overall, 10% of cases had sufficient symptoms to meet IBS diagnostic criteria. A further 27% met all criteria except 6 months' duration and another 23% had several features of IBS but did not fulfil strict Rome III criteria. There was no significant difference between C. parvum and C. hominis infection with regard to PI-IBS. Post-infectious gastrointestinal dysfunction and fatigue were commonly reported after cryptosporidiosis. Fatigue and abdominal pain were significantly more common after C. hominis compared to C. parvum infection. Around 10% of people had symptoms meriting a formal diagnosis of IBS following cryptosporidiosis. Using age-specific Rome III criteria, children as well as adults were shown to be affected.

Entities:  

Keywords:  Cryptosporidiosis; Cryptosporidium hominis; Cryptosporidium parvum; Irritable bowel syndrome; Sequelae

Year:  2019        PMID: 31302785     DOI: 10.1007/s10096-019-03603-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

Review 1.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 2.  Persistent Symptoms After Treatment of Lyme Disease.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2022-09       Impact factor: 5.905

3.  Outbreak of Cryptosporidium hominis in northern Sweden: persisting symptoms in a 5-year follow-up.

Authors:  Malin Sjöström; M Arvidsson; L Söderström; M Lilja; J Lindh; M Widerström
Journal:  Parasitol Res       Date:  2022-04-22       Impact factor: 2.383

4.  Health sequelae of human cryptosporidiosis in industrialised countries: a systematic review.

Authors:  Bethan L Carter; Rachel M Chalmers; Angharad P Davies
Journal:  Parasit Vectors       Date:  2020-09-04       Impact factor: 3.876

Review 5.  Use-case scenarios for an anti-Cryptosporidium therapeutic.

Authors:  Paul G Ashigbie; Susan Shepherd; Kevin L Steiner; Beatrice Amadi; Natasha Aziz; Ujjini H Manjunatha; Jonathan M Spector; Thierry T Diagana; Paul Kelly
Journal:  PLoS Negl Trop Dis       Date:  2021-03-11

Review 6.  Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome.

Authors:  Ao Liu; Wenkang Gao; Yixin Zhu; Xiaohua Hou; Huikuan Chu
Journal:  Toxins (Basel)       Date:  2022-08-29       Impact factor: 5.075

7.  Cross-sectional household transmission study of Cryptosporidium shows that C. hominis infections are a key risk factor for spread.

Authors:  Caoimhe McKerr; Rachel M Chalmers; Kristin Elwin; Heather Ayres; Roberto Vivancos; Sarah J O'Brien; Robert M Christley
Journal:  BMC Infect Dis       Date:  2022-02-02       Impact factor: 3.090

8.  Extracts of pine bark (Pinus sylvestris) inhibit Cryptosporidium parvum growth in cell culture.

Authors:  Berit Marie Blomstrand; Heidi Larsen Enemark; Øivind Øines; Håvard Steinshamn; Inga Marie Aasen; Karl-Christian Mahnert; Kristin Marie Sørheim; Spiridoula Athanasiadou; Stig Milan Thamsborg; Ian David Woolsey
Journal:  Parasitol Res       Date:  2021-07-16       Impact factor: 2.289

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.